Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial

Journal of the American Academy of Dermatology

Volumn 64, Issue 1, 2011, Pages 64-70

  Langley, Richard G ^a   Paller, Amy S ^b   Hebert, Adelaide A ^c   Creamer, Kara ^d   Weng, Haoling H ^d   Jahreis, Angelika ^d   Globe, Denise ^d   Patel, Vaishali ^d   Orlow, Seth J ^e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d AMGEN INC   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Children's Dermatology Life Quality Index; Harter Self Perception Profile for Children; health related quality of life; pediatric plaque psoriasis; Pediatric Quality of Life Inventory; Stein Impact on Family Scale

Indexed keywords

ETANERCEPT; PLACEBO;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MAXIMUM TOLERATED DOSE; PATIENT SATISFACTION; PSORIASIS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650307698     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2010.02.060     Document Type: Article

References (23)

1. K. Zappel, W. Sterry, and U. Blume-Peytavi Therapy options for psoriasis in childhood and adolescence [German] J Dtsch Dermatol Ges 2 2004 329 342
2. M. Rogers Childhood psoriasis Curr Opin Pediatr 14 2002 404 409
3. J. Leman, and A.D. Burden Recognition and treatment of psoriasis in children Curr Paediatr 13 2003 418 422
4. S.P. Raychaudhuri, and J. Gross A comparative study of pediatric onset psoriasis with adult onset psoriasis Pediatr Dermatol 17 2000 174 178
5. G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, and T. Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
6. A.S. Paller, E.C. Siegfried, R.G. Langley, A.B. Gottlieb, D. Pariser, and I. Landells Etanercept treatment for children and adolescents with plaque psoriasis N Engl J Med 358 2008 241 251
7. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed January 14, 2010.
8. M.S. Lewis-Jones, and A.Y. Finlay The children's dermatology life quality index (CDLQI): initial validation and practical use Br J Dermatol 132 1995 942 949
9. S.A. Holme, I. Man, J.L. Sharpe, P.J. Dykes, M.S. Lewis-Jones, and A.Y. Finlay The children's dermatology life quality index: validation of the cartoon version Br J Dermatol 148 2003 285 290
10. Wales College of Medicine Department of Dermatology. Dermatology life quality index questionnaire. Available from: URL: http://www.dermatology.org.uk/ index.asp?portal/quality/dlqi.html. Accessed December 9, 2008.
11. J.W. Varni, M. Seid, T. Smith Knight, T. Burwinkle, J. Brown, and I.S. Szer The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the pediatric quality of life inventory generic core scales and rheumatology module Arthritis Rheum 46 2002 714 725 (Pubitemid 34214252)
12. R.E. Stein, and C.K. Riessman The development of an impact-on-family scale: preliminary findings Med Care 18 1980 465 472
13. R.E. Stein, and D.J. Jessop The impact on family scale revisited: further psychometric data J Dev Behav Pediatr 24 2003 9 16
14. A.R. Williams, U. Piamjariyakul, P.D. Williams, S.K. Bruggeman, and R.L. Cabanela Validity of the revised impact on family (IOF) scale J Pediatr 149 2006 257 261
15. L. Wichstrom Harter's self-perception profile for adolescents: reliability, validity, and evaluation of the question format J Pers Assess 65 1995 100 116
16. S. Harter Manual for the self-perception profile for children 1985 University of Denver Denver (CO)
17. G.R. Norman, J.A. Sloan, and K.W. Wyrwich Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation Med Care 41 2003 582 592
18. J.W. Varni, T.M. Burwinkle, M. Seid, and D. Skarr The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity Ambul Pediatr 3 2003 329 341
19. P.E. Beattie, and M.S. Lewis-Jones A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases Br J Dermatol 155 2006 145 151
20. S.R. Feldman, A.B. Kimball, G.G. Krueger, J.M. Woolley, D. Lalla, and A. Jahreis Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial J Am Acad Dermatol 53 2005 887 889 (Pubitemid 41501389)
21. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
22. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
23. S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial Lancet 367 2006 29 35